TABLE 6.
Comparison of TRC150094 50 and 150 mg with placebo for percentage change of pharmacodynamic markers using Dunnett’s test while adjusting for the change in body weight.
| Comparison | Apo B | Triglycerides | MATSUDA index | HOMA-IR | Hepatic fat by MRS |
|---|---|---|---|---|---|
| Difference between means 95% CI (LL-UL), p value | Difference between means 95% CI (LL-UL), p value | Difference between means 95% CI (LL-UL), p value | Difference between means 95% CI (LL-UL), p value | Difference between means 95% CI (LL-UL), p value | |
| TRC150094 50 mg–Placebo | −22.49a (−40.12, -4.85), 0.01 | −43.01 (−89.54, 3.51), 0.07 | −17.66 (−163.45, 128.12), 0.93 | −89.00 (−324.63, 146.62), 0.56 | −4.57 (−26.58, 17.44), 0.84 |
| TRC150094 150 mg–Placebo | −12.33 (−31.02, 6.35), 0.21 | −19.83 (−69.13, 29.47), 0.49 | 94.34 (−60.14, 248.81), 0.24 | −29.19 (278.87–220.48), 0.83 | −0.27 (−23.59, 23.06), 0.99 |
a
Comparisons significant at the 0.05 level. 95% CI (LL-UL):95% Confidence Interval (CI) (Lower limit, Upper limit).
Abbreviation: ApoB, apolipoprotein B, HOMA-IR, Homeostatic model assessment-insulin resistance; MRS, magnetic resonance spectroscopy.